Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06322862

FLuorescence Guided Assessment of Mesenteric Ischemia in Emergency Surgery

This is a prospective, multicentre, non-randomized cohort study using real-time intraoperative visualization of bowel perfusion by indocyanine green (ICG) in all-cause bowel ischemia.

At intraoperative finding of bowel ischemia, the initial intraoperative plan is noted and resection margins marked with a steril pen. A fluorescence angiography will be performed and the surgeon will note whether the suspected ischemic bowel is perfused, whether there is a change in the resection margins in centimeters, and if the intraoperative plan has changed. If resection is indicated and the strategy of choice is an anastomosis, a renewed fluorescence angiography will be performed to assess anastomotic perfusion.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Department of Organ Surgery and Transplantation, Copenhagen, Capital Region, Denmark

Loading trial locations.

About this study

Fluorescence guided-surgery utilises the fluorescent property of a fluorophore, indocyanine green (ICG), injected intravenously to assess perfusion and viability of the bowel.

This study aims to evaluate the usability and feasibility of ICG to assess bowel viability in an emergency abdominal surgery setting where all-cause bowel ischemia is suspected and intraoperatively present. The investigators aim to evaluate whether ICG fluorescence angiography contributes as an intraoperative aid and changes the intraoperative strategy.

The investigators hypothesize that ICG is a safe and reliable aid in intraoperative decision-making regarding mesenteric ischemia. It may lead to an increasing number of one-step definitive procedures with vital resection margins, primary anastomosis and reducing stomas, and second-look procedures.

In this prospective, non-randomized cohort study bowel viability will be assessed using intraoperative real-time visualization by performing an ICG-fluorescence angiography when there is intraoperative finding of bowel ischemia.

Intraoperatively, ICG (Verdye, Diagnostic Green GmbH 25 mg vials) are dissolved with 5 ml sterile water obtaining a concentration of 5 mg/ml. 0,2mg/kg will be administered intravenously at one to two steps of perfusion assessment.

Initially, the surgeon notes the intended intraoperative plan before fluorescing and if resection is deemed necessary, the resection margins will be marked with a sterile pen.

The perfusion assessment with ICG is then performed and perfusion of the suspected ischemic bowel is noted, along with any change in intended resection margins and intraoperative plan. If an anastomosis is performed, a renewed perfusion assessment is performed. The perfusion assessment will be recorded.

Postoperatively, a subgroup of suitable perfusion assessment recordings will be subject to quantification software using software developed and validated by the investigators (q-ICG).

The trial follows regulations for research in emergency settings and a written and oral informed consent will be obtained from the participant or the participants next of kin and a trial guardian, postoperatively.

Intra- and postoperative clinical data will be collected, including choice of strategy, anastomotic leaks, 30- and 90- day complications, and mortality rates.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients >18 years of age
  • Acute physiologic derangement and suspected of having bowel ischemia
  • Intraoperative finding of all-cause bowel ischemia with subsequent acute physiologic derangement

Exclusion criteria

  • Allergy toward; iodine, indocyanine green, or shellfish
  • Liver insufficiency
  • Thyrotoxicosis
  • Pregnancy or lactation
  • Permanently legally incompetent for any reason

Treatment and study plan

Indocyanine green

Other

Intraoperative perfusion assessment with ICG Fluorescence Angiography (ICG-FA) in standard approved doses

Primary outcomes

  1. Change of strategy

    Time frame: Assessed at day 30 and 90 after surgery

    Change of intraoperative strategy due to ICG fluorescence angiography. Intraoperatively, a nurse will record the initial strategy, indication of resection in centimeters, before and after ICG angiography, and note whether there has been a change in strategy, and how.

Secondary outcomes

  1. Anastomosis

    Time frame: Assessed at day 30 and 90 after surgery

    Number of anastomoses established in ICG-perfused bowel segments

  2. Quantification using q-ICG

    Time frame: 30 months

    A posthoc perfusion quantification using q-ICG software

  3. Stomas

    Time frame: Assessed at day 30 and 90 after surgery

    Number of cases where stoma was the preferred strategy

  4. Second-look

    Time frame: Assessed at day 30 and 90 after surgery

    Number of cases where second-look following bowel discontinuation, was the preferred strategy

  5. Anastomotic leaks

    Time frame: Assessed at day 30 and 90 after surgery

    Cases of anastomotic leaks postoperatively

  6. Postoperative medical complications

    Time frame: Assessed at day 30 and 90 after surgery

    Stratified by type and severity (Comprehensive Complication Index)

  7. Postoperative surgical complications

    Time frame: Assessed at day 30 and 90 after surgery

    Stratified by type and severity (Comprehensive Complication Index)

  8. Mortality

    Time frame: 90 days

    30- and 90-day mortality rates

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Patrick Achiam, MD, PhD, DMSc

CONTACT

[email protected]

+45 3545 0441

Sermed Ellebæk Nicolae, MD, PhD-student

CONTACT

[email protected]

+45 3545 9666

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

Intraoperative Intestinal Perfusion Assessment by Fluorescence Angiography in Emergency Surgery

Acronym: FLAMES

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Mar 21, 2024
Registry last updated
Nov 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.